SCHEMBL5017702

SCHEMBL5017702

CCC(=O)Nc1cc(-n2cc(C)cn2)nc(-c2ccco2)n1

nearest known ligand 0.63

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 13/20 0.63
ADORA2A P29274 13/20 0.63
ADORA3 P0DMS8 9/20 0.63
ADORA2B P29275 6/20 0.63
ALDH1A1 P00352 2/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5017646 0.84 ADORA2A (0.80) ADORA1ADORA2AADORA3ADORA2B
SCHEMBL5016141 0.83 ADORA2A (0.64) ADORA1ADORA2AADORA3ADORA2BALDH1A1
SCHEMBL5017739 0.83 ADORA2A (0.64) ADORA1ADORA2AADORA3ADORA2BMEN1
SCHEMBL5022651 0.82 ADORA1 (0.69) ADORA1ADORA2AADORA3ADORA2BALDH1A1
SCHEMBL5017648 0.82 ADORA2A (0.65) ADORA1ADORA2AADORA3ADORA2BMEN1
SCHEMBL5016122 0.79 ADORA1 (0.68) ADORA1ADORA2AADORA3ADORA2BALDH1A1
SCHEMBL8288702 0.79 ADORA2A (0.74) ADORA1ADORA2AADORA3ADORA2B
SCHEMBL5016112 0.78 ADORA2A (0.60) ADORA1ADORA2AADORA3ADORA2BALDH1A1
SCHEMBL5016140 0.76 ADORA1 (0.77) ADORA1ADORA2AADORA3ADORA2B
SCHEMBL5016303 0.76 ADORA2A (0.64) ADORA1ADORA2AADORA3ADORA2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US claimed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ADORA1 3/4885ADORA2A 1/4885ADORA3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.